Kambis Mashayekhi: Microcatheter selection and manipulation- How to make the ...Euro CTO Club
14th Experts Live CTO
September 2nd - 3rd, 2022 - Mainz, Germany
Main Session - Lunch Symposium by Asahi:
Road to CTO expert 2022 – how to build your CTO toolkit
Microcatheter selection and manipulation- How to make the right choice
Kambis Mashayekhi, Lahr, Germany
Room:
Guteberg Hall (Auditorium) - Saturday 13:30
Speaker:
Gerald Werner, Darmstadt, Germany;
Kambis Mashayekhi, Lahr, Germany;
Jo Dens, Genk, Belgium;
Gregor Leibundgut, Bâle, Suisse
Microcatheters for antegrade and retrograde approachEuro CTO Club
Microcatheters for antegrade and retrograde approach
George Sianos, Thessaloniki, Greece
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
Kambis Mashayekhi: Microcatheter selection and manipulation- How to make the ...Euro CTO Club
14th Experts Live CTO
September 2nd - 3rd, 2022 - Mainz, Germany
Main Session - Lunch Symposium by Asahi:
Road to CTO expert 2022 – how to build your CTO toolkit
Microcatheter selection and manipulation- How to make the right choice
Kambis Mashayekhi, Lahr, Germany
Room:
Guteberg Hall (Auditorium) - Saturday 13:30
Speaker:
Gerald Werner, Darmstadt, Germany;
Kambis Mashayekhi, Lahr, Germany;
Jo Dens, Genk, Belgium;
Gregor Leibundgut, Bâle, Suisse
Microcatheters for antegrade and retrograde approachEuro CTO Club
Microcatheters for antegrade and retrograde approach
George Sianos, Thessaloniki, Greece
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
Coronary CTO is characterized by heavy atherosclerotic plaque burden within the artery, resulting in complete (or nearly complete) occlusion of the vessel. Although the duration of the occlusion is difficult to determine on clinical grounds, a total occlusion must be present for at least 3 months to be considered a true CTO. Patients with CTO typically have collateralization of the distal vessel on coronary angiography, but these collaterals may not provide sufficient blood flow to the myocardial bed, resulting in ischemia and anginal symptoms. CTO is clinically distinct from acute coronary occlusion, which occurs in the setting of ST-segment–elevation myocardial infarction, or subacute coronary occlusion, discovered with delayed presentation after ST-segment–elevation myocardial infarction. Clinical features and treatment considerations of these entities differ considerably from CTO.
Among patients who have a clinical indication for coronary angiography, the incidence of CTO has been reported to be as high as 15% to 30%. Patients with CTO are referred for angiography because of anginal symptoms or significant ischemia on noninvasive ischemia testing. Patients who are symptomatic will have stable exertional angina resulting from a limitation of collateral vessel flow to meet myocardial oxygen demand with stress. Of patients referred for PCI in clinical trials of CTO PCI, only 10% to 15% of patients are asymptomatic. It is likewise uncommon for patients with CTO to present with an acute coronary syndrome caused by the CTO itself.
Percutaneous balloon dilatation, first described by
Andreas Gruentzig in 1979, was initially performed
without the use of guidewires.1 The prototype
balloon catheter was developed as a double lumen
catheter (one lumen for pressure monitoring or
distal perfusion, the other lumen for balloon inflation/deflation) with a short fixed and atraumatic
guidewire at the tip. Indeed, initially the technique
involved advancing a rather rigid balloon catheter
freely without much torque control into a coronary
artery. Bends, tortuosities, angulations, bifurcations,
and eccentric lesions could hardly, if at all, be negotiated, resulting in a rather frustrating low procedural success rate whenever the initial limited
indications (proximal, short, concentric, noncalcified) were negated.2 Luck was almost as
important as expertise, not only for the operator,
but also for the patient. It is to the merit of
Simpson who, in 1982, introduced the novelty of
advancing the balloon catheter over a removable
guidewire, which had first been advanced in the
target vessel.3 This major technical improvement
resulted overnight in a notable increase in the procedural success rate. Guidewires have since evolved
into very sophisticated devices.
Retrograde approach step-by-step
Kambis Mashayekhi, Bad Krozingen, Germany
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
Perforation management of collaterals
Kambis Mashayekhi, Bad Krotzingen, Germany
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
Coronary CTO is characterized by heavy atherosclerotic plaque burden within the artery, resulting in complete (or nearly complete) occlusion of the vessel. Although the duration of the occlusion is difficult to determine on clinical grounds, a total occlusion must be present for at least 3 months to be considered a true CTO. Patients with CTO typically have collateralization of the distal vessel on coronary angiography, but these collaterals may not provide sufficient blood flow to the myocardial bed, resulting in ischemia and anginal symptoms. CTO is clinically distinct from acute coronary occlusion, which occurs in the setting of ST-segment–elevation myocardial infarction, or subacute coronary occlusion, discovered with delayed presentation after ST-segment–elevation myocardial infarction. Clinical features and treatment considerations of these entities differ considerably from CTO.
Among patients who have a clinical indication for coronary angiography, the incidence of CTO has been reported to be as high as 15% to 30%. Patients with CTO are referred for angiography because of anginal symptoms or significant ischemia on noninvasive ischemia testing. Patients who are symptomatic will have stable exertional angina resulting from a limitation of collateral vessel flow to meet myocardial oxygen demand with stress. Of patients referred for PCI in clinical trials of CTO PCI, only 10% to 15% of patients are asymptomatic. It is likewise uncommon for patients with CTO to present with an acute coronary syndrome caused by the CTO itself.
Percutaneous balloon dilatation, first described by
Andreas Gruentzig in 1979, was initially performed
without the use of guidewires.1 The prototype
balloon catheter was developed as a double lumen
catheter (one lumen for pressure monitoring or
distal perfusion, the other lumen for balloon inflation/deflation) with a short fixed and atraumatic
guidewire at the tip. Indeed, initially the technique
involved advancing a rather rigid balloon catheter
freely without much torque control into a coronary
artery. Bends, tortuosities, angulations, bifurcations,
and eccentric lesions could hardly, if at all, be negotiated, resulting in a rather frustrating low procedural success rate whenever the initial limited
indications (proximal, short, concentric, noncalcified) were negated.2 Luck was almost as
important as expertise, not only for the operator,
but also for the patient. It is to the merit of
Simpson who, in 1982, introduced the novelty of
advancing the balloon catheter over a removable
guidewire, which had first been advanced in the
target vessel.3 This major technical improvement
resulted overnight in a notable increase in the procedural success rate. Guidewires have since evolved
into very sophisticated devices.
Retrograde approach step-by-step
Kambis Mashayekhi, Bad Krozingen, Germany
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
Perforation management of collaterals
Kambis Mashayekhi, Bad Krotzingen, Germany
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
Which CTO should be treated by PCI or CABG & The specific problems of PCI for...Euro CTO Club
Which CTO should be treated by PCI or CABG & The specific problems of PCI for post CABG patients
Gerald S. Werner, Darmstadt, Germany
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
15th Experts Live CTO - Carlo Di Mario: ConclusionsEuro CTO Club
PLENARY SESSION
Wrap up of live cases, awards to the winners of the best abstracts and case competitions and take home messages
Auditorium Zubin Mehta - Saturday 16:00 - 17:00
Speakers:
Daniela Benedetto (Rome),
Francesco Burzotta (Rome),
Carlo Di Mario (Florence),
Roberto Garbo (Turin),
Rocco Stio (Rome)
Challengers:
Stelios Pyxaras (Furth - D),
Sudhir Rathore (London - UK)
Discussants:
Shunsuke Matsuno (Tokyo - J),
Alexander Nap (Amsterdam - NL),
Masahisa Yamane (Tokyo - J)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Francesco Burzotta: Wrap up Gemelli CasesEuro CTO Club
PLENARY SESSION
Wrap up of live cases, awards to the winners of the best abstracts and case competitions and take home messages
Auditorium Zubin Mehta - Saturday 16:00 - 17:00
Speakers:
Daniela Benedetto (Rome),
Francesco Burzotta (Rome),
Carlo Di Mario (Florence),
Roberto Garbo (Turin),
Rocco Stio (Rome)
Challengers:
Stelios Pyxaras (Furth - D),
Sudhir Rathore (London - UK)
Discussants:
Shunsuke Matsuno (Tokyo - J),
Alexander Nap (Amsterdam - NL),
Masahisa Yamane (Tokyo - J)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Jonathan Hill: Role of mechanica support in CTO recanalizationEuro CTO Club
10:42
Role of mechanica support in CTO recanalization
Jonathan Hill (London - UK)
___________________________________________
PARALLEL SESSION
Challenges And Opportunities In Cto Recanalization
Auditorium Zubin Mehta - Saturday 10:00 - 11:10
Chairperson:
Jonathan Hill (London - UK)
Discussants:
Lesnek Bryniarski (Krakow - PL),
Ugo Fabrizio (Vercelli),
Paul Knaapen (Amsterdam - NL),
Eugenio La Scala (Ollioiouls - F)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Gregor Leibundgut: Role of DEB in CTO-PCIEuro CTO Club
10:35 Role of DEB in CTO-PCI
Gregor Leibundgut (Basel - CH)
___________________________________________
PARALLEL SESSION
Challenges And Opportunities In Cto Recanalization
Auditorium Zubin Mehta - Saturday 10:00 - 11:10
Chairperson:
Jonathan Hill (London - UK)
Discussants:
Lesnek Bryniarski (Krakow - PL),
Ugo Fabrizio (Vercelli),
Paul Knaapen (Amsterdam - NL),
Eugenio La Scala (Ollioiouls - F)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Kambis Mashayekhi: EuroCTO Consensus on treatment of Calcified CTO lesion Eur...Euro CTO Club
AUDITORIUM ZUBIN MEHTA
08/09/2023 04:30 - 05:20
PLENARY SESSION - INTERVENTIONAL CTO & CHIP RESEARCH Best CTO Publications 2022-23 (selected by the Editors of the Cardiology Interventional journals)
Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...Euro CTO Club
16:53
CTO PCI Outcome associated with poor quality of the distal target vessel
Emmanouil Brilakis (Minneapolis - USA)
_____________________________________________
PARALLEL SESSION
Interventional CTO & Chip Research
Best CTO Publications 2022-23 (selected by the Editors of the Cardiology Interventional journals)
Auditorium Zubin Mehta - Friday 16:30 - 17:16
Chairpersons:
Davide Capodanno (Catania),
Carlo Di Mario (Florence),
Giuseppe Tarantini (Padua)
Panelist:
Roberto Diletti (Rotterdam - NL),
Giovanni Esposito (Naples),
Paul Knaapen (Amsterdam - NL),
Maksymilian Opolski (Warsaw - PL)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Mario Iannaccone - 2 EuroCTO Consensus on Guide Catheter Extensions JACC Card...Euro CTO Club
16:33
EuroCTO Consensus on Guide Catheter Extensions JACC Cardiovasc Interventions
Mario Iannaccone (Turin)
_____________________________________________
PARALLEL SESSION
Interventional CTO & Chip Research
Best CTO Publications 2022-23 (selected by the Editors of the Cardiology Interventional journals)
Auditorium Zubin Mehta - Friday 16:30 - 17:16
Chairpersons:
Davide Capodanno (Catania),
Carlo Di Mario (Florence),
Giuseppe Tarantini (Padua)
Panelist:
Roberto Diletti (Rotterdam - NL),
Giovanni Esposito (Naples),
Paul Knaapen (Amsterdam - NL),
Maksymilian Opolski (Warsaw - PL)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
Kambis Mashayekhi: Keynote: My essential tipps & tricks for success in complication management
1. My essential tipps & tricks for
success in complication
management
Kambis Mashayekhi
Heart Center Lahr
2. Affiliation/Financial Relationship
• Consulting Fees/Honoraria
Company
• Abboth, Abiomed, Ashai Intecc, Astra
Zeneca, Biotronik, Boston, Cardinal
Health, Daiichi Sankyo, Medtronic,
Schockwave, SIS, Teleflex,Terumo,
Disclosures
Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or
affiliation with the organization(s) listed below.
3. Patel S et al J Invasive Cardiol. 2018
Perforation, mortality, and tamponade are the
three most concerning complications in CTO PCI
Survey of 1,149 cardiologists on CTO PCI
4. Failed CTO cases have a higher
complication rate and higher mortality
3,9 3,6 3,4
4,2
10,3
9,8 10,2
8,6
0,1 0,3 0 0,1
1,5
0,5 0,4 0,2
0
2
4
6
8
10
12
2008-2009 2010-2011 2012-2013 2014-2015
Complication
rate
(%)
Any periprocedural complication, successful cases
Any periprocedural complication, failed cases
In hospital mortality, successful cases
In hospital mortality, failed cases
17,626 procedures enrolled in ERCTO (2008-2015)
Konstantinidis NV et al. ; Circ Cardiovasc Interv. 2018 Oct;11(10):
5. Update from the PROGRESS CTO Registry: 2018
Tajti P. et al, JACC Cardiovasc Interv. 2018
AWE: J-CTO 2.28 ADR: J-CTO 2.86 Retrograde: J-CTO 3.12
6. 4,3
2,1
0,4
1,3
0,6
0,8
1,1
0,3 0,3 0,3
0,1 0,1
0
M
A
C
E
M
I
S
t
r
o
k
e
P
e
r
i
c
a
r
d
i
o
c
e
n
t
e
s
i
s
R
e
-
P
C
I
D
e
a
t
h
Complication
rate
(%)
Retrograde
Antegrade-only
PROspective Global REgiStry for the
Study of CTO interventions
MACCE in retrograde vs. antegrade-only CTO
Karmpaliotis et al. Circ Cardiovasc Interv 2016 Jun
n=539 J-CTO 3,1
n=762 J-CTO 2,5
8. Periprocedural Myocardial Injury in Patients Undergoing
CTO-PCI : Role of Antegrade and Retrograde Crossing
Techniques
Toma et al, EuroIntervention. 2018
antegrade; n=1447
19,4% PMI
retrograde; n=462
44,2% PMI
PMI (elevation of cardiac troponin T [cTnT] >5 x 99th percentile of normal)
12. Ipsilateral collaterals in RCA-CTO
After changing the MC
from Supercross to Corsair
Dunning Dissection – Typ I
1) STOP antegrade contrast injection
2) Disconnect your contrast syringe
3) Fix the ostium with a stent
17. Iatrogenic Aortic Dissection
1) STOP antegrade contrast injection
2) Use guideliner to protect the aorto-
coronary ostium if contrast is needed for
distal stenting
3) Fix the ostium with a stent (or even
covered stent)
4) Conservative and no surgical
treatment after fixing the problem!!!
21. Aortic dissection
1) STOP antegrade contrast injection
2) Use guideliner to protect the aorto-
coronary ostium if contrast is needed for
distal stenting
3) Fix the ostium with a stent (or even
covered stent)
4) Conservative and no surgical
treatment after fixing the problem!!!
32. Complications in collaterals
1) Never do a superselectiv injection in
damaged collaterals
2) Flushing the fat in the MC is the
major failure mechanism if you want
to embolize with fat
3) Coil the antegrade and retrograde
blood supply, after successful CTO
35. Coronary perforation during CTO PCI
European Multicenter Registry including 1811 patients with 99 perforations (5.5%)
Azallini L, Poletti E, Ayoub M, ……,Mashayekhi K., EuroIntervention 2019
36. Coronary perforation during CTO PCI
European Multicenter Registry including 1811 patients with 99 perforations
(5.5%), totale rate of tamponade (0,9%)
Tamponade: 20%
Death: 5,5%
Azallini L, Poletti E, Ayoub M, ……,Mashayekhi K., EuroIntervention 2019
37. Coronary perforation during CTO PCI
Open CTO Registry including 1000 patients with 89 perforations (8.9%),
totale rate of tamponade (1,0%)
Hirai et al., JACC Cardiovasc Interv. 2019 Jun 19
Tamponade: 23.3%
Death: 20.9%
46. Epicardial Perforation
Coiling:
1) Pushable coils
2) Compatible MC
Solve the problem immediately!
Do not hesitate!
STOP contrast Injection
Pericardial Effusion?
Post-CABG: hematoma?
How to treat epicardial collateral perforations?
ACT measurement
Protamine only if:
Drainage in the pericardial, or after
successful mechanical embolization
Fat-Embolization/Thrombin:
1) Fat from groin; Fat floats
2) Do no inject it / push it with a
wire!!!
3) Negative suction through MC
51. Guideliner assisted Revers-CART Final result
Antegrade Device Perforation
1) Long balloon deflation
2) Retrograde “Rescue” CTO
3) Use a guideliner distal of the perforation
for stenting
4) CrossBoss use should be limited to short distal
advancement (<15-20mm) in a straight
segment for performing a controlled dissection
for placing your stingray balloon
52. By courtesy of A. Büttner
RCA CTO post CABG
Retrograde epicardial access LCX to PLB
54. After first stents:
main vessel perforation type III
After 10 stents:
5 x 38mm DES (190mm)
5 x covered stents (19,19,16,16,12mm
RCA CTO post CABG
Retrograde epicardial access LCX to PLB
55. Hematoma with compression of left atrium
→ Hemodynamics: PA syst 40 mmHg; CI 2.0 l/min/m²
Cardiac CT (Day 1)
1) Post-CABG hematoma are the most
life-threatening complications in
CTO-PCI
2) Use of knuckle wire and polymer
jacket wires in unclear vessel routes
are safer, and should be preferred
over stiff penetration wires!!!
56. Day 6 Day 14
Echo
1) Post-CABG hematoma are the most
life-threatening complications in
CTO-PCI
2) Use of knuckle wire and polymer
jacket wires in unclear vessel routes
are safer, and should be preferred
over stiff penetration wires!!!
74. Comparison of patients with/without rotablation in the Bad Krozingen CTO DATABASE:
2789 patients with CTO PCI in stable Angina during 5 years (2015-2019)
CTO with Rotablation CTO without Rotablation
Total number of patients (%) 193 (6.9%) 2596 (93.1%) 2789 (Patients)
Rota 106 (55%)
RotaPro 87 (45%)
History of CABG 60 (33.5%) 417 (16.7%) <0.0001
Procedural time in min. 127 [94-186] 81 [51-126] <0.0001
Fluoroscopy time in min. 54 [35-80] 35 [20-60] <0.0001
Contrast volume in cc 310 [200-400] 260 [190-390] 0.0032
Radiation dose in mGy 1339 [806-2353] 1762 [1231-2555] 0.24
Tamponade 6 (3.1%) 13 (0.5%) <0.0001
In-hospital MI SCAI 24 (12.5%) 142 (5.6%) <0.0001
In-hospital MI 4a 3 (1.6%) 47 (1.8%) 0.80
In-hospital MACCE 8 (4.2%) 72 (2.8%) 0.27
3-year MACCE 45 (23.3%) 554 (21.3%) 0.52
75. Aorto coronary
dissection
1) Stop contrast media
2) Disconnect your contrast syringe
3) Fix the aortocoronary ostium with
a stent (or even cover stent)
4) Use guide extensions
5) Once the entry is fix = conservative,
no surgical treatment
1) Avoid overrotation of
microcatheters and wires
2) Avoid wire kink during
externalization (RG 3)
3) Do not pull hard outside the body
4) Try to trap or better snare out
entrapped devices
Managing CTO Complications
Device
entrapment
76. Perforations
1. STOP to inject contrast
2. Long Balloon deflation
3. Retrograde Rescue
4. Stenting (Coverstent?)
Managing CTO Complications
Antegrade Device
Perforation
After Stenting
Stenting
Collateral
Perforation
1. STOP to inject contrast
2. Long Balloon deflation
3. Ping Pong Technique
4. Coverstent
1. STOP to inject contrast
2. During retrograde wiring:
a. Balloon inflation, Coiling from retrograde
3. After successful CTO:
a. Coiling from ante and retrograde